| Drug ID: | Drug44 |
|---|---|
| Drug Name: | Methylprednisolone |
| CID: | 6741 |
| DrugBank ID: | DB00959 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00152620, , NCT05587673, , NCT02921555, , NCT03219359 |
| Molecular Formula: | C22H30O5 |
| Molecular Weight: | 374.5 g/mol |
| Isomeric SMILES: | C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O |
| Synonyms: | methylprednisolone; 83-43-2; Medrone; 6alpha-Methylprednisolone; Metilbetasone; Dopomedrol; Medesone; Mesopren; Metastab; Metrisone |
| Phase 0: | 14 |
| Phase 1: | 97 |
| Phase 2: | 303 |
| Phase 3: | 205 |
| Phase 4: | 184 |
| Description: | A prednisolone derivative with similar anti-inflammatory action. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt403 | 6741 | Methylprednisolone | 7157 | TP53 | Homo sapiens (human) | None | |
| dt404 | 6741 | Methylprednisolone | 3689 | ITGB2 | Homo sapiens (human) | None | |
| dt405 | 6741 | Methylprednisolone | 5243 | ABCB1 | Homo sapiens (human) | 16932953 | ABCB1 gene polymorphism affects the susceptibility to [methotrexate co-treated with methylprednisolone]|abcb1 protein results in increased susceptibility to [methotrexate co-treated with methylprednisolone] |
| dt406 | 6741 | Methylprednisolone | 5243 | ABCB1 | Homo sapiens (human) | 22464980 | Valspodar inhibits the reaction [ABCB1 protein results in increased secretion of methylprednisolone]|elacridar inhibits the reaction [ABCB1 protein results in increased secretion of methylprednisolone]|abcb1 protein results in increased secretion of methy |
| dt407 | 6741 | Methylprednisolone | 5243 | ABCB1 | Homo sapiens (human) | 22079615 | Methylprednisolone results in increased expression of ABCB1 mRNA |
| dt408 | 6741 | Methylprednisolone | 5243 | ABCB1 | Homo sapiens (human) | Methylprednisolone results in increased expression of ABCB1 protein | |
| dt409 | 6741 | Methylprednisolone | 9429 | ABCG2 | Homo sapiens (human) | 15365089 | Methylprednisolone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
| dt410 | 6741 | Methylprednisolone | 57007 | ACKR3 | Homo sapiens (human) | 19192274 | Methylprednisolone results in decreased expression of ACKR3 mRNA |
| dt411 | 6741 | Methylprednisolone | 135 | ADORA2A | Homo sapiens (human) | 19192274 | Methylprednisolone results in decreased expression of ADORA2A mRNA |
| dt412 | 6741 | Methylprednisolone | 207 | AKT1 | Rattus norvegicus (Norway rat) | Methylprednisolone results in decreased phosphorylation of AKT1 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT01941589 | Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis | PHASE4 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DRUG: oral 5-ASA+/-topical 5-ASA+IV corticosteroi… | Details |
| NCT03219359 | Autologous Stem Cell Transplant for Crohn's Disease | PHASE2 | RECRUITING | Aaron Etra | Crohn Disease | PROCEDURE: Autologous stem cell transplant|DRUG: … | Details |
| NCT00152620 | Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease | None | TERMINATED | University of Chicago | Inflammatory Bowel Disease (IBD) | DRUG: Dexamethasone|DRUG: Methylprednisolone | Details |
| ISRCTN23541842 | The auxiliary diagnostic value of fissured tongue on axial and peripheral joint dysfunction in Ankylosing Spondylitis | Not Available | Not Recruiting | Zhejiang University Of Chinese Medicine | Ankylosing spondylitis Musculoskeletal Diseases … | Participants are screened and undergo a clinical … | Details |
| NCT05587673 | High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD) | PHASE1 | COMPLETED | Stanford University | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | DRUG: Methylprednisolone | Details |
| NCT05867329 | A Trial for Acute Severe Ulcerative Colitis | PHASE4 | RECRUITING | Berinstein, Jeffrey | Ulcerative Colitis Acute | DRUG: Cyclosporine Injection (IV)|DRUG: Cyclospor… | Details |
| NCT02921555 | Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DRUG: Methylprednisolone|DRUG: Prednisone | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Possible genetical predictors of efficacy and safety of budesonide-MMX in patie…
PMID: 36811412
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Budesonide-MMX is a topically active corticosteroid degraded by cytochrome-P450 enzymes, resulting in favorable side-effect profile. We a…
The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric …
PMID: 34690297
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Administering medications prior to infliximab infusions to prevent infusion-related infliximab reactions is a common practice in the United States. H…
The Association of methylprednisolone dosing to cessation of myotonia in a pati…
PMID: 32312586
Year: 2020
Relationship Type:
Treatment
Score: 6.5
We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis i…
Glycyrrhizin enhances therapeutic activity of a colon-specific methylprednisolo…
PMID: 23192646
Year: 2013
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Co-administration of a reduction inhibitor and a colon-specific prodrug of a glucocorticoid susceptible to colonic reductive metabolism i…